Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 30;23(1):21.
doi: 10.1186/s12991-024-00507-z.

Treating depression in patients with borderline personality disorder: clinical clues on the use of antidepressants

Affiliations
Review

Treating depression in patients with borderline personality disorder: clinical clues on the use of antidepressants

Carmine Tomasetti et al. Ann Gen Psychiatry. .

Abstract

Personality disorders (PD) are described as enduring patterns of markedly deviant and pervasive inner experiences and behaviors, with onset in adolescence, which lead to severe distress or impairment. Patients suffering from major depressive disorder (MDD) display higher rates of comorbidity with personality disorders, often complicating the treatment, and worsening the outcomes. Borderline personality disorder (BPD) is the most common of PD and is frequently associated with MDD, with which shares several features. The most part of research agrees on the fact that comorbid BPD in MDD patients quite doubles the poor response to treatments. Moreover, no treatment strategy stands out currently to emerge as more effective in these cases, thus urging the call for the need of new approaches. Herein, we revise the current literature on BPD, its neurobiology and comorbidity with MDD, as well as the more recent treatment strategies used. Then, based on its pharmacology, we propose a possible role of trazodone as a valuable tool to approach comorbid BPD-MDD.

Keywords: Comorbidity; Emotion; Neurobiology; Psychiatric disorders; Serotonin antagonist/Reuptake inhibitors; Trazodone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx) [Internet]. [cited 2023 Feb 26]. https://vizhub.healthdata.org/gbd-results/.
    1. Pigott HE. The STAR*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. Can J Psychiatry [Internet]. 2015 [cited 2023 Mar 11];60:9. https:/pmc/articles/PMC4314062/. - PMC - PubMed
    1. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr Dis Treat [Internet]. 2020 [cited 2023 Mar 14];16:221. /pmc/articles/PMC6982454/. - PMC - PubMed
    1. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry. 2005;162:1911–8. doi: 10.1176/appi.ajp.162.10.1911. - DOI - PubMed
    1. Friborg O, Martinsen EW, Martinussen M, Kaiser S, Overgård KT, Rosenvinge JH. Comorbidity of personality disorders in mood disorders: a meta-analytic review of 122 studies from 1988 to 2010. J Affect Disord. 2014;152–154:1–11. doi: 10.1016/j.jad.2013.08.023. - DOI - PubMed